Takeaway
- In patients with uncontrolled type 2 diabetes (T2D) on 1-3 oral anti-diabetic drugs (OADs), once-weekly (OW) semaglutide 1.0 mg was superior to once-daily liraglutide 1.2 mg in improving glycaemic control and reducing body weight.
Why this matters
- The efficacy and safety of OW semaglutide have been investigated in the SUSTAIN phase 3 clinical trial programme across the continuum of care in patients with T2D.
- In line with findings of the LEADER trial, the SUSTAIN 6 trial showed that semaglutide significantly reduced the risk for major adverse cardiovascular (CV) events compared with placebo in patients with T2D and high CV risk.
Study design
- SUSTAIN 10 study of 569 patients with T2D on 1-3 OADs who were randomly assigned (1:1) to receive subcutaneous OW semaglutide 1.0 mg (n=287) or once-daily liraglutide 1.2 mg (n=282).
- Main outcomes: changes in haemoglobin A1c (HbA1c) and body weight from baseline to 30 weeks.
- Funding: Novo Nordisk.
Key results
- At 30 weeks, semaglutide was superior to liraglutide in reducing mean:
- HbA1c level (estimated treatment difference [ETD], −0.69%; 95% CI, −0.82 to −0.56).
- body weight (ETD, −3.83 kg; 95% CI, −4.57 to −3.09; P<.0001 for both).
- A greater proportion of patients achieved HbA1c level <7.0% and ≤6.5%, weight loss of ≥5% and ≥10% and a composite endpoint of HbA1c <7.0% without severe or blood glucose-confirmed symptomatic hypoglycaemia and weight gain with semaglutide vs liraglutide (P<.0001 for all).
- Both treatments had similar safety profiles, except for most frequent gastrointestinal disorders (43.9% vs 38.3%) and adverse events leading to premature treatment discontinuation (11.4% vs 6.6%) with semaglutide vs liraglutide.
Limitations
- Open-label design.
- Short-duration trial.
References
References
